AVI BioPharma, Inc. (AVII) Tops Q3 EPS by 3c; Guides FY11 Sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
Total other non operating income: -209K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Total other non operating income: -209K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q3 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06).
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- OPENLANE, Inc. (OPLN) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
